Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Prostatic Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Sarcoma, Kaposi 3Neoplasms 3Breast Neoplasms 3Acquired Immunodeficiency Syndrome 3Uterine Cervical Neoplasms 2Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Neoplasm Metastasis 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hodgkin Disease 2HIV Infections 2Glioma 2Glioblastoma 2Endometrial Neoplasms 2Brain Neoplasms 2Wilms Tumor 1Weight Loss 1Vulvar Neoplasms 1Vaginal Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Tongue Neoplasms 1Thyroid Cancer, Papillary 1Thrombocytopenia 1Splenomegaly 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Sezary Syndrome 1

Interventions

Oxaliplatin 29Fluorouracil 25Leucovorin 20Capecitabine 18Irinotecan 17Bevacizumab 14Cisplatin 12Surveys and Questionnaires 11Gemcitabine 9Drug Therapy 9Standard of Care 8Nivolumab 7Cetuximab 7pembrolizumab 6S 1 (combination) 6Cyclophosphamide 6atezolizumab 5Specimen Handling 5Endoscopic Mucosal Resection 5Educational Status 5Docetaxel 5Blood Specimen Collection 5fludarabine 4aldesleukin 4Radiotherapy 4Radiosurgery 4Pemetrexed 4IFL protocol 4Folfox protocol 4Everolimus 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Gastrointestinal Neoplasms × Ritonavir × Clear all
NCT05150691 2026-01-28

A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors

DualityBio Inc.

Phase 1/2 Recruiting
796 enrolled
BreastGastrointestinalGynecologicThoracic

Bile Duct Neoplasms, Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Liver Neoplasms, Neoplasm Metastasis, Neoplasms, Recurrence, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡